NCT05570539View on ClinicalTrials.gov

Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 7, 2022

Primary Completion Date

May 2, 2024

Study Completion Date

July 1, 2024

Conditions
CoughHealthy
Interventions
DRUG

BLU-5937 IR

Each subject will receive two single and multiple administrations of Immediate Release reference formulation

DRUG

BLU-5937 ER

Each subject will receive single and multiple oral administrations of Extended Release formulation

Trial Locations (1)

NG11 6JS

GSK Investigational Site, Nottingham

All Listed Sponsors
lead

Bellus Health Inc. - a GSK company

INDUSTRY